دورية أكاديمية
Secukinumab in plaque psoriasis--results of two phase 3 trials.
| العنوان: | Secukinumab in plaque psoriasis--results of two phase 3 trials. |
|---|---|
| المؤلفون: | Langley, Richard G, Elewski, Boni E, Lebwohl, Mark, Reich, Kristian, Griffiths, Christopher E M, Papp, Kim, Puig, LluÃs, Nakagawa, Hidemi, Spelman, Lynda, Sigurgeirsson, Bárður, Ghislain, Pierre-Dominique, Rivas, Enrique, Tsai, Tsen-Fang, Wasel, Norman, Tyring, Stephen, Salko, Thomas, Hampele, Isabelle, Notter, Marianne, Karpov, Alexander, Helou, Silvia, Papavassilis, Charis |
| المساهمون: | UCL - Autre |
| المصدر: | New England Journal of Medicine, Vol. 371, no.4, p. 326-338 (2014) |
| بيانات النشر: | Massachusetts Medical Society |
| سنة النشر: | 2014 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Adult, Infection, Injections, Subcutaneous, Interleukin-17, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents |
| الوصف: | Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | Ndonga |
| تدمد: | 0028-4793 1533-4406 |
| العلاقة: | boreal:157510; http://hdl.handle.net/2078.1/157510Test; info:pmid/25007392; urn:ISSN:0028-4793; urn:EISSN:1533-4406 |
| DOI: | 10.1056/NEJMoa1314258 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1314258Test http://hdl.handle.net/2078.1/157510Test |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.703D2CE |
| قاعدة البيانات: | BASE |
| تدمد: | 00284793 15334406 |
|---|---|
| DOI: | 10.1056/NEJMoa1314258 |